RxDoctor Payments Data

Brian Wagoner

Family · Springfield, MONPI 1306083480

Payments from drug & device makers

$2,474in general payments, 2019–2025

Across 46 payments — averaging $53.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • AbbVie$320
  • Pfizer$234
  • Genentech USA, Inc.$147
  • AstraZeneca$122
  • Amgen$122
  • plus $299 from 4 others

What the payments were for

  • Travel & lodging$70729%
  • Food & beverage$1,75171%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,474 in reported general payments places this provider in the 80th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$33,756
Medicare patients
260
Services billed
368

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AubagioTeriflunomide21$190,085
Aimovig AutoinjectorErenumab-Aooe149$142,329
UbrelvyUbrogepant82$102,627
Emgality PenGalcanezumab-Gnlm101$92,311
Nurtec OdtRimegepant Sulfate66$91,958
CopaxoneGlatiramer Acetate12$84,000
QuliptaAtogepant57$69,238
Ajovy AutoinjectorFremanezumab-Vfrm28$30,175
TopamaxTopiramate12$23,101
FingolimodFingolimod Hcl25$10,270
NamzaricMemantine Hcl/Donepezil Hcl12$6,970
Gabapentin310$5,493
Levetiracetam258$4,999
Memantine Hcl268$4,240
Oxcarbazepine36$3,782

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Namzaric$320$178,835151 claims
PfizerNurtec Odt$234$91,95866 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,812 family providers in Missouri.

Other family in Springfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →